EMN Stock Analysis: Eastman Chemical | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 7.517m USD | 12M Return: 6.5% | US2774321002 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 84.1M
EPS Trend: -42.2%
Qual. Beats: 1
Rev. Trend: -68.0%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Eastman Chemical Company (NYSE: EMN) is a U.S.-based specialty materials company founded in 1920 and headquartered in Kingsport, Tennessee, operating across four reportable segments: Additives & Functional Products, Advanced Materials, Chemical Intermediates, and Fibers. Its product portfolio spans amine derivatives, specialty polymers, copolyesters, cellulosic biopolymers, olefin and acetyl derivatives, plasticizers, and cellulose acetate tow and yarns, serving end-markets such as transportation, construction, personal care, agriculture, electronics, medical, and filtration (notably cigarette filters). The company generates revenue globally, with operations in the United States, China, and other international markets, and is classified within the Materials sectors Diversified Chemicals sub-industry as a mid-cap stock. As a diversified chemicals producer, Eastman combines specialty, higher-margin offerings with commodity chemical and intermediate products, a structure that exposes it to both industrial cyclicality and demand for value-added materials in consumer and durable goods applications.
- Acetate tow demand pressured by declining global cigarette consumption
- Molecular recycling capacity expansion drives circular plastics revenue
- Additives and Functional Products margins squeezed by raw material volatility
- Construction and durables demand weakness weighs on Advanced Materials volumes
| Net Income: 442.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.81 > 1.0 |
| NWC/Revenue: 15.96% < 20% (prev 17.60%; Δ -1.63% < -1%) |
| CFO/TA 0.06 > 3% & CFO 991.0m > Net Income 442.0m |
| Net Debt (4.53b) to EBITDA (1.27b): 3.56 < 3 |
| Current Ratio: 1.50 > 1.5 & < 3 |
| Outstanding Shares: last quarter (115.3m) vs 12m ago -0.77% < -2% |
| Gross Margin: 19.88% > 18% (prev 24.04%; Δ -4.16% > 0.5%) |
| Asset Turnover: 57.86% > 50% (prev 61.02%; Δ -3.16% > 0%) |
| Interest Coverage Ratio: 3.52 > 6 (EBIT TTM 749.0m / Interest Expense TTM 213.0m) |
| A: 0.09 (Total Current Assets 4.25b - Total Current Liabilities 2.84b) / Total Assets 15.4b |
| B: 0.66 (Retained Earnings 10.2b / Total Assets 15.4b) |
| C: 0.05 (EBIT TTM 749.0m / Avg Total Assets 15.3b) |
| D: 0.66 (Book Value of Equity 6.10b / Total Liabilities 9.25b) |
| Altman-Z'' = 3.78 = AA |
| DSRI: 1.07 (Receivables 1.36b/1.34b, Revenue 8.87b/9.29b) |
| GMI: 1.21 (GM 24.04% / 19.88%) |
| AQI: 0.99 (AQ_t 0.36 / AQ_t-1 0.36) |
| SGI: 0.95 (Revenue 8.87b / 9.29b) |
| TATA: -0.04 (NI 442.0m - CFO 991.0m) / TA 15.4b) |
| Beneish M = -2.82 (Cap -4..+1) = A |
As of October 08, 2026, the stock is trading at USD 63.25 with a total of 1,591,037 shares traded. Over the past week, the price has changed by -2.45%, over one month by -9.00%, over three months by -8.00% and over the past year by +6.52%.
Current recommended Stop Loss: 61.10 (which is 3.4% or 1.2 ATR below the current price).
Eastman Chemical has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy EMN.
- StrongBuy: 6
- Buy: 3
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 81.6 | 29% |
P/E Trailing = 17.3026
P/E Forward = 9.1996
P/S = 0.8479
P/B = 1.2528
P/EG = 0.514
Revenue TTM = 8.87b USD
EBIT TTM = 749.0m USD
EBITDA TTM = 1.27b USD
Long Term Debt = 4.20b USD (from longTermDebt, last fiscal year)
Short Term Debt = 765.0m USD (from shortTermDebt, last quarter)
Debt = 5.22b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.53b USD (calculated: Debt 5.22b - CCE 691.0m)
Enterprise Value = 12.0b USD (7.52b + Debt 5.22b - CCE 691.0m)
Interest Coverage Ratio = 3.52 (Ebit TTM 749.0m / Interest Expense TTM 213.0m)
EV/FCF = 22.34x (Enterprise Value 12.0b / FCF TTM 539.0m)
FCF Yield = 4.48% (FCF TTM 539.0m / Enterprise Value 12.0b)
FCF Margin = 6.08% (FCF TTM 539.0m / Revenue TTM 8.87b)
Net Margin = 4.99% (Net Income TTM 442.0m / Revenue TTM 8.87b)
Gross Margin = 19.88% ((Revenue TTM 8.87b - Cost of Revenue TTM 7.10b) / Revenue TTM)
Gross Margin QoQ = 22.28% (prev 19.80%)
Tobins Q-Ratio = 0.78 (Enterprise Value 12.0b / Total Assets 15.4b)
Interest Expense / Debt = 4.08% (Interest Expense 213.0m / Debt 5.22b)
Taxrate = 17.66% (95.0m / 538.0m)
NOPAT = 616.7m (EBIT 749.0m * (1 - 17.66%))
Current Ratio = 1.50 (Total Current Assets 4.25b / Total Current Liabilities 2.84b)
Debt / Equity = 0.86 (Debt 5.22b / totalStockholderEquity, last quarter 6.10b)
Debt / EBITDA = 3.56 (Net Debt 4.53b / EBITDA 1.27b)
Debt / FCF = 8.40 (Net Debt 4.53b / FCF TTM 539.0m)
Total Stockholder Equity = 5.96b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.88% (Net Income 442.0m / Total Assets 15.4b)
RoE = 7.42% (Net Income TTM 442.0m / Total Stockholder Equity 5.96b)
RoCE = 7.37% (EBIT 749.0m / Capital Employed (Equity 5.96b + L.T.Debt 4.20b))
RoIC = 4.78% (NOPAT 616.7m / Invested Capital 12.9b)
WACC = 6.83% (E(7.52b)/V(12.7b) * Re(9.23%) + D(5.22b)/V(12.7b) * Rd(4.08%) * (1-Tc(0.18)))
Discount Rate = 9.23% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.42 | Cagr: -1.10%
[DCF] Terminal Value 77.97% ; FCFF base≈487.0m ; Y1≈558.3m ; Y5≈821.6m
[DCF] Fair Price = 68.56 (EV 12.4b - Net Debt 4.53b = Equity 7.84b / Shares 114.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -42.21 | EPS CAGR: -8.19% | SUE: 1.28 | # QB: 1
Revenue Correlation: -68.00 | Revenue CAGR: -2.09% | SUE: 2.43 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.95 | Chg30d=-0.22% | Revisions=+36% | Analysts=13
EPS current Year (2026-12-31): EPS=6.38 | Chg30d=-0.19% | Revisions=-7% | GrowthEPS=+17.6% | GrowthRev=+5.9%
EPS next Year (2027-12-31): EPS=6.89 | Chg30d=-0.65% | Revisions=+21% | GrowthEPS=+8.0% | GrowthRev=+1.7%
[Analyst] Revisions Ratio: +19% (up=20, down=13)